drugset / Trial / NCT04422899

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

NCT04422899

Phase 1 Completed 3 enrolled AiViva BioPharma, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

To determine safety, pharmacokinetics, and duration of effect of intravitreally administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration

Timeline

Start
2020-08-28
Primary completion
2021-09-29
Completion
2022-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject AIV007 Unknown Intravitreal
Subject Lenvatinib Small molecule Intravitreal